Stanford researchers have found evidence that an RNA sequence called “Xist,” which is only produced by biologically female (XX) mammals, is an important factor in the etiology of many autoimmune diseases (Image: Sergii Laramenko/Shutterstock)
The
statistics have been clear and consistent for decades: autoimmune conditions are
at least three times more common among women than men. Some studies suggest
it’s more like a factor of four. For specific diseases like Lupus, the
disparity is 9-fold. For Sjogren’s syndrome, it’s 19 to 1.
This
appears to be an objective biological phenomenon. It’s not a reflection of
gender-based differences in seeking medical care, or of misdiagnosis—though
there’s plenty of that. Neither is it strictly hormone-related.
Hormonal
factors do play some role in autoimmune disorders. But the hormonal differences
between biologically female and male individuals in no way fully account for
the marked disparity of autoimmune diseases.
The presence of micro- or nano-plastic particles in carotid atheromas significantly raises the risk of myocardial infarction, stroke, or death from any cause within 3 years. That’s the blunt conclusion of a new multi-center study headed by researchers at the Department of Advanced Medical & Surgical Science, University of Campania, Naples, and involving more than […]
Eczema is seldom life-threatening, but it can have profoundly detrimental impact on the people it affects. Clinicians who can bring a holistic, root-cause approach to this common condition can make a big difference in the lives of their patients. “Roughly 20 million Americans have eczema. It’s a huge population. Patients are desperate for help, and […]
Risk assessment is a foundation of good clinical
practice. Accurate and individualized risk prediction allows for informed
decision-making, enhanced disease screening and personalized risk-reduction
strategies for your patients.
We’re all aware of the use of penetrant genes
like BRCA1/2 as genomic markers for cancer susceptibility. But there is
a lesser-known disease susceptibility indicator known as polygenic risk
score (PRS), that can be highly valuable in clinical practice.
In this FREE webinar, Dr. Joel Evans will
explore the role of PRS in clinical decision-making. He’ll highlight the value
of PRS when integrated with other clinical risk factors in assessing a patient’s
risk of developing disease, and describe how to implement this type of
clinically-integrated genetic technology in longevity-focused precision
medicine practice.
As a
women’s healthcare practitioner with a passion for hormone replacement therapy,
Dr. Evans will focus specifically on the benefits of PRS for breast cancer risk
assessment. He’ll also touch on application of the same technology for other
cancers including ovarian, colorectal, pancreatic, prostate and melanoma, and
other common disorders like type 2 diabetes and heart disease.
With PRS assessment, you can now offer your patients the latest in disease risk
prediction to create personalized treatment plans to increase health span,
wellness, and longevity.
You’ll learn:
The
basics of predictive genomics in the context of polygenic risk
How
assessment of polygenic risk, in combination with other clinical risk factors, can
positively impact your implementation of longevity medicine
Practical
approaches for utilizing the latest in genomic-integrated clinical risk
prediction into your clinical practice
Joel Evans, MD, is Chief Medical Officer at geneType, and is a board-certified OB/GYN and international lecturer. He is the Director of The Center for Functional Medicine in Ridgefield, CT, and Chief of Medical Affairs for the Institute for Functional Medicine. Dr. Evans is renowned for his passion for mind-body medicine. His special interest in breast cancer led him to serve as the Medical Director of the Keep A Breast Foundation. Dr. Evans brings decades of applied research about cancer risk and prevention to his patients, and to the functional medicine community.
